ArticleEye (London, England)2026
The burden of near vision loss from 1990 to 2021, and projections until 2032-findings from the Global Burden of Disease Study 2021.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNear vision loss (NVL) represents a major global health challenge. However, its epidemiological research is less extensive compared to that of distance vision impairment. To fill this gap, this study examined worldwide patterns in NVL prevalence and disease burden from 1990 to 2021 and forecasted trends up to 2032.
methodsUsing data from the Global Burden of Disease (GBD) 2021 study, which covers 204 countries and territories, we assessed four key epidemiological measures: prevalence, disability-adjusted life years (DALYs), age-standardised prevalence rates (ASPRs), and age-standardised DALY rates (ASDRs). Future trends through 2032 were predicted employing Bayesian age-period-cohort (BAPC) modelling.
resultsBetween 1990 and 2021, global ASPRs for NVL rose by 37% (95% UI: 28-46%), and ASDRs increased by 38% (29-47%). In 2021, over 1.1 billion people worldwide were affected by NVL, leading to 11.6 million DALYs. The low-middle socio-demographic index (SDI) regions showed the highest ASPRs (16,252.9 per 100,000) and ASDRs (162.8 per 100,000), with females consistently experiencing higher rates than males. Projections suggest that ASPRs will continue to rise through 2032.
conclusionsWith the growing burden of NVL, it remains a significant global health issue. Consequently, focused allocation of resources toward NVL prevention and management is essential. Particular attention should be given to older adults and women, who are more susceptible to this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.